Omicron variant of the coronavirus can partially evade the protection from Pfizer and partner BioNTech's vaccine, new research shows
The Omicron variant of the coronavirus can partially evade the protection from Pfizer Inc and partner BioNTech's Covid-19 vaccine,, citing the research head of a laboratory at Africa Health Research Institute in South Africa.
Sigal said on Twitter there was "a very large drop" in neutralisation of the Omicron variant relative to an earlier strain of Covid. Blood from five out of six people who had been vaccinated as well as previously infected with Covid-19 still neutralised the Omicron variant, the manuscript said. The Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Omicron significantly reduces Covid antibody protection in small study of Pfizer vaccine recipients
続きを読む »
Pfizer CEO says omicron appears milder but spreads faster and could lead to more Covid mutations
続きを読む »
Mix-and-match J&J Covid booster raised immune response after Pfizer vaccine, study findsUsing the Johnson & Johnson vaccine as a booster for people initially immunized with the Pfizer/BioNTech vaccine produces a strong immune response and may do more to elicit protection against severe disease, researchers reported Sunday.
続きを読む »
WSJ CEO Council: Leaders from Tesla, Intel, Reddit, Pfizer and More Discuss Challenges Facing BusinessThe Wall Street Journal is gathering prominent leaders in business and politics to discuss how CEOs can best navigate the current political and economic climate.
続きを読む »
Omicron significantly reduces Covid antibody protection in small study of Pfizer vaccine recipients
続きを読む »